Press
October 6, 2020

NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass., Oct. 6, 2020 (SEND2PRESS NEWSWIRE) — NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour,…
News
September 2, 2020

Leading Experts in Cancer Research Nabeel El-Bardeesy and Razelle Kurzrock Join NED Biosystems’ Scientific Advisory Board

CAMBRIDGE, Mass., Sept. 2, 2020 (SEND2PRESS NEWSWIRE) — NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy,…
News
November 14, 2019

NED Biosystems Unveils First Peer-Reviewed Presentation at ASCO Breakthrough Summit

Promising outcomes for advanced cancers associated with novel investigational cancer therapeutic   Cambridge, Mass., October 13, 2019 – NED Biosystems, Inc., a clinical-stage biotech company investigating solutions for a broad range of…
News
October 17, 2019

World-Renowned Cancer Leader Brian Leyland-Jones Named Chairman of NED Biosystems’ Scientific Advisory Board

Cambridge, Mass., October 17, 2019 – NED Biosystems, a clinical-stage biotech company investigating solutions for a broad range of cancers, is pleased to announce Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRCPC,…
News
July 10, 2019

Founding Director of DARPA Biological Technologies Office, Geoffrey Ling, Appointed CEO of NED Biosystems

Ling brings significant medical insight, strategic vision and dynamic implementation to guide NED Biosystems’ development of unique cancer treatment combination Cambridge, Mass., July 10, 2019 – NED Biosystems, a clinical-stage biotech…
NewsPress
April 29, 2019

NED Biosystems Gains Patent for Unique Combination Therapy

Hennessy’s Highlights – The Latest Oncology News from Mike Hennessy, Jr., President – OncLive.com April 2019 Biotechnology company NED Biosystems is developing a novel therapeutic that integrates 7 compounds into a…
NewsPress
February 9, 2019

BioWorld: NED Biosystems assembles 7-pronged attack on cancer

See full story here: http://www.bioworld.com/report/BWT02082019NED.pdf By Michael Fitzhugh, News Editor, BioWorld Volume 30, No. 27 February 8, 2019 NED Biosystems Inc., a Cambridge, Mass.-based venture developing a seven-agent combination therapy…
News
February 7, 2019

First-of-its-kind Composition Patent Awarded to NED Biosystems for 7-Agent Combination Cancer Therapeutic

Paves Way for NED-170 Clinical Trials and FDA Submission Cambridge, MA, February 7, 2019 – NED Biosystems, a clinical-stage biotech company investigating solutions for a range of cancers, today announced…
News
August 1, 2018

NED Biosystems Raises $2 Million in Series B Financing Round and Appoints New CEO

Company Announces New Members to Scientific Advisory Board Including Nobel Laureate Dudley Herschbach, Ph.D. Cambridge, MA, August 1, 2018 – NED Biosystems, a clinical-stage biotech company developing a unique oral oncologic combination…